Welcome to our dedicated page for Venus Concept news (Ticker: VERO), a resource for investors and traders seeking the latest updates and insights on Venus Concept stock.
Venus Concept Inc. (VERO) delivers innovative medical aesthetic and hair restoration technologies through its unique subscription-based model. This dedicated news hub provides investors and industry professionals with essential updates on corporate developments, product advancements, and strategic initiatives shaping the global aesthetics market.
Access real-time announcements including quarterly earnings reports, regulatory filings, technology launches, and partnership agreements. Our curated collection ensures you stay informed about VERO's minimally invasive treatment systems, international expansion efforts, and clinical research breakthroughs without promotional bias.
Key coverage areas include financial performance updates, new device approvals, practice support program enhancements, and market expansion activities. Each update is verified for accuracy and presented in clear, accessible language suitable for both professional investors and industry observers.
Bookmark this page for streamlined access to Venus Concept's evolving business narrative. Check regularly for authoritative reporting on how VERO continues integrating advanced technologies like radiofrequency systems and IPL platforms with practice growth initiatives across 60+ countries.
Venus Concept (NASDAQ: VERO) reported a 19% year-over-year increase in total revenue for Q3 2021, reaching $24.6 million. U.S. revenue surged 67% to $13.0 million, while international revenue dropped 10%. The gross margin improved to 70.5%, up 5.2% percentage points. However, the GAAP net loss attributable to stockholders increased 35% to $9.8 million. The company also tightened its fiscal year 2021 revenue guidance to anticipate a growth of 33% to 37%.
Venus Concept, a leader in medical aesthetic technology, announces management's participation in the Stifel 2021 Virtual Healthcare Conference on November 17th at 4:00 p.m. ET. An audio webcast of the session will be available on their investor relations website, and a replay will follow the event. The company operates in over 60 countries, focusing on a subscription-based model for its diverse product portfolio, which includes devices for aesthetic procedures and hair restoration systems like NeoGraft and ARTAS.
Venus Concept (NASDAQ: VERO) announced FDA 510(k) clearance to market the Venus Freedom device in the U.S. This non-invasive device offers non-thermal radiofrequency treatment combined with massage and magnetic field pulses, targeting minor muscle aches and improving local blood circulation. CEO Domenic Serafino expressed optimism about expanding their technology portfolio, following previous Health Canada authorization for Venus Fiore. A limited launch is expected in Q1 2022. Venus Concept's innovative business model aims to provide attractive returns for the OBGYN community.
Venus Concept (NASDAQ: VERO) announced the appointment of Ross J. Portaro as President of Global Sales, effective October 15, 2021. He replaces Chad A. Zaring, who is resigning but will remain as a consultant until March 31, 2022. Portaro, previously Vice President of EMEA, brings over 30 years of healthcare experience. His leadership aims to strengthen the company's sales organization and enhance customer satisfaction. Venus Concept is recognized as an innovator in medical aesthetic technology, with a diverse product portfolio and operations in over 60 countries.
Venus Concept (NASDAQ: VERO) will announce its Q3 fiscal 2021 financial results on November 12, 2021, prior to market opening. A conference call is scheduled for 8:00 a.m. ET that day, featuring a Q&A session. Participants can join via phone with access code 13723892 or through a live webcast on their investor relations website. Venus Concept specializes in medical aesthetic technologies with a subscription-based sales model across more than 60 countries. The company offers a wide range of aesthetic devices and hair restoration systems, and is supported by prominent healthcare investors.
Venus Concept, a leader in medical aesthetic technology, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Management's presentation will be available on-demand starting September 13 at 7:00 a.m. Eastern Time. Additionally, virtual investor meetings are scheduled for September 14. The presentation can be accessed via the Company's investor relations website, with a replay available post-conference. Venus Concept operates in over 60 countries, offering a range of minimally and non-invasively aesthetic and hair restoration technologies.
Venus Concept (NASDAQ: VERO) reported robust Q2 2021 financial results, with total revenue of $25.8 million, a 52% increase year-over-year. The company's gross margin improved to 72.5%, and GAAP operating income surged by 117% to $1.5 million. Net income also saw a significant rise, reaching $0.4 million. The company upgraded its full-year revenue guidance to between $102.0 million and $107.0 million, representing a projected growth of 31% to 37%. Recent product developments and collaborations further bolster its market position.
Venus Concept, a leader in medical aesthetic technology, announced its participation in the Sidoti & Co. Microcap Conference to be held virtually on August 18-19, 2021. Management will present on August 18 at 8:30 a.m. ET. An audio webcast of the presentation will be available on the Company's investor relations website, with an archive for later replay.
With a diverse product range, including minimally invasive aesthetic devices and hair restoration systems, Venus Concept operates in over 60 countries. The Company favors a subscription-based sales model in North America and direct markets.
Venus Concept (NASDAQ: VERO) has received a medical device license from Health Canada to market the Venus Fiore Feminine Health System. This follows the CE Mark received in March 2020. The limited launch in Canada and the EU is expected in Q3 2021.
The Venus Fiore system uniquely addresses feminine health issues, providing three non-surgical treatments: internal vaginal, labia tightening, and mons pubis skin tightening. Designed for post-menopausal women, it aims to enhance sexual quality of life and improve physical appearance.
Venus Concept, a leader in medical aesthetic technology, will participate in the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 2:30 p.m. ET. An audio webcast of the presentation will be available on the company’s investor relations website, with an archive for later access.
The company operates a subscription-based business model, offering a wide range of devices for minimally invasive and non-invasive aesthetic treatments and hair restoration systems worldwide.
FAQ
What is the current stock price of Venus Concept (VERO)?
What is the market cap of Venus Concept (VERO)?
